This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Based in New Haven, CT, Alexion Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of life-transforming drugs, for the treatment of patients with ultra-rare disorders. The company’s complement franchise consists of key growth driver, Soliris, which is approved for the treatment of two severe and ultra-rare disorders resulting from chronic uncontrolled activation of the complement component of the immune system — paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). Soliris is also approved for the treatment of generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) antibody-positive. The FDA also approved its long-acting C5 complement inhibitor, Ultomiris, for the treatment of adult patients with PNH, to be administered every eight weeks. In October 2019, the FDA approved the use of Ultomiris as a treatment for adult and pediatric (one month of age or older) patients with aHUS to inhibit complement-mediated TMA.
Intra-Cellular (ITCI) Soars: Stock Adds 27.7% in Session
by Zacks Equity Research
Intra-Cellular (ITCI) saw a big move last session, as its shares jumped nearly 28% on the day amid huge volumes.
Paratek Pharmaceuticals, Inc. (PRTK) Catches Eye: Stock Up 27.3%
by Zacks Equity Research
Paratek Pharmaceuticals, Inc. (PRTK) was a big mover last session, as the company saw its shares rise over 27% on the day came after news leaked that the company is considering a sale.
Immunomedics (IMMU) Catches Eye: Stock Up 5.1%
by Zacks Equity Research
Immunomedics (IMMU) was a big mover last session, as the company saw its shares rise over 5% on the day amid huge volumes.
Biotech Stock Roundup: EU Label Expansion for Alexion, BIIB Facing Drug Price Probe
by Arpita Dutt
Key highlights include regulatory approvals for companies like Alexion (ALXN) and Ironwood while Biogen is one of the companies facing an investigation into the pricing of multiple sclerosis drugs.
Immunomedics' Progress in Phase II Cancer Study Encouraging
by Zacks Equity Research
Immunomedics, Inc. (IMMU) announced encouraging interim results from a phase II study on its cancer candidate, labetuzumab govitecan. Shares were up 7% on Monday in response.
4 Biotech Stocks to Add to your Portfolio Post Q2 Earnings
by Arpita Dutt
Here is a look at four biotech stocks including Gilead (GILD) that topped estimates in Q2 and are witnessing upward estimate revisions for the current year.
Alexion's (ALXN) Soliris' Label Expansion Approved in Europe
by Zacks Equity Research
Alexion Pharmaceuticals (ALXN) announced that the European Commission (EC) approved a label expansion of lead drug Soliris which should further boost sales.
Intec Pharma (NTEC) Catches Eye: Stock Adds 9.8% in Session
by Zacks Equity Research
Intec Pharma Ltd. (NTEC) moved big last session, as its shares rose more than 9% on the day.
Falling Earnings Estimates Signal Weakness Ahead for Adamas (ADMS)
by Zacks Equity Research
One stock that you may want to consider dropping is Adamas Pharmaceuticals, Inc. (ADMS), which has witnessed a significant price decline in the past four weeks
Mirati Therapeutics (MRTX) Rises: Stock Moves 10.9% Higher
by Zacks Equity Research
Mirati Therapeutics, Inc. (MRTX) moved big last session, as its shares rose almost 11% on the day.
Horizon Pharma (HZNP) Soars: Stock Adds 10.5% in Session
by Zacks Equity Research
Horizon Pharma Public Limited Company (HZNP) was a big mover last session, as the company saw its shares rise nearly 11% on the day amid huge volumes.
Seattle Genetics' Adcetris Granted Priority Review by FDA
by Zacks Equity Research
Seattle Genetics, Inc.'s (SGEN) supplemental Biologics License Application for Adcetris in patients with cutaneous T-cell lymphoma has been accepted by the FDA and granted priority review.
Novo Nordisk's Semaglutide Shows Remarkable Results in Study
by Zacks Equity Research
Novo Nordisk (NVO) pipeline candidate shows superior glucose control and weight loss in study in diabetes patients compared with Eli Lilly and Co's Trulicity (dulaglutide).
Spectrum (SPPI) Initiates Phase II Study for Cancer Drug
by Zacks Equity Research
Spectrum Pharmaceuticals, Inc. (SPPI) initiated the registrational phase III study of qapzola in patients with non-muscle invasive bladder cancer (NMIBC) as per the FDA's requirement.
Shire Files Marketing Application for Lifitegrast in Europe
by Zacks Equity Research
Shire plc (SHPG) submitted a Marketing Authorization Application (MAA) for lifitegrast for the treatment of dry eye disease in Europe.
MiMedx Group (MDXG) in Focus: Stock Moves 6.1% Higher
by Zacks Equity Research
MiMedx Group (MDXG) was a big mover last session, as the company saw its rise over 6% on the day amid huge volumes.
Regeneron vs. Alexion: Which Stock is a Better Pick Post Q2 Earnings?
by Arpita Dutt
Biotech companies, Regeneron (REGN) and Alexion, both topped estimates in Q2 and raised their outlook. But, which stock is better-positioned for the second half of the year?
Editas Medicine (EDIT) Looks Good: Stock Moves Up 11.3%
by Zacks Equity Research
Editas Medicine, Inc. (EDIT) moved big moved last session, as its shares rose over 11% on the day.
Forget Teva (TEVA), Buy These 4 Drug Stocks Instead
by Arpita Dutt
With generic drugmakers like Teva (TEVA) under pressure, here is a look at four drug stocks that look well-positioned.
Implied Volatility Surging for Alexion Pharmaceuticals (ALXN) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Alexion Pharmaceuticals (ALXN) stock based on the movements in the options market lately.
Puma (PBYI) Q2 Loss Narrower than Expected, Nerlynx in Focus
by Zacks Equity Research
Puma Biotechnology (PBYI) reported narrower-than-expected loss in Q2. Shares were down in after-hours trading.
Geron (GERN) Q2 Loss Narrows, Sales Miss Estimates, Stock Up
by Zacks Equity Research
Geron Corporation (GERN) reported narrower-than-expected loss in Q2 while sales missed estimates. Shares were up in after-hours trading.
Forget Bayer, Buy These 3 Drug Stocks Instead
by Arpita Dutt
With Bayer (BAYRY) reporting mixed results in the second quarter and lowering its outlook, here is a look at 3 drug stocks which look well positioned.
Dynavax Technologies (DVAX) Catches Eye: Stock Adds 11.2% in Session
by Zacks Equity Research
Dynavax Technologies Corporation (DVAX) was a big mover last session, as the company saw its shares rise over 11% on the day.
New Strong Buy Stocks for August 2nd
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday